The ClinicianThe ClinicianКлиницист1818-83382412-8775Publishing House ABV Press10910.17650/1818-8338-2011-3-95-102PHARMACOTHERAPYФАРМАКОТЕРАПИЯTHE ROLE OF CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME AFTER THE EMERGENCE OF MORE POWERFUL INHIBITORS OF P2Y12 RECEPTORРОЛЬ КЛОПИДОГРЕЛА В ЛЕЧЕНИИ БОЛЬНЫХ С ОСТРЫМ КОРОНАРНЫМ СИНДРОМОМ ПОСЛЕ ПОЯВЛЕНИЯ БОЛЕЕ МОЩНЫХ ИНГИБИТОРОВ РЕЦЕПТОРОВ P2Y12GilyarevskyS. R.ГиляревскийС. Р.
Russian Federation
sgilarevsky@rambler.ruLarinA. G.ЛаринА. Г.
Russian Federation
LopotovskyP. Y.ЛопотовскийП. Ю.
Russian Federation
KuzminaI. M.КузьминаИ. М.
Russian Federation
BaturinaO. V.БатуринаО. В.
Russian Federation
Emergency Care Scientific-Research Institute named N.V. SklifosovskyНИИ скорой помощи им. Н.В. Склифосовского1507201153951021707201417072014Copyright ©; 2011, Gilyarevsky S.R., Larin A.G., Lopotovsky P.Y., Kuzmina I.M., Baturina O.V.Copyright ©; 2011, Гиляревский С.Р., Ларин А.Г., Лопотовский П.Ю., Кузьмина И.М., Батурина О.В.2011Gilyarevsky S.R., Larin A.G., Lopotovsky P.Y., Kuzmina I.M., Baturina O.V.Гиляревский С.Р., Ларин А.Г., Лопотовский П.Ю., Кузьмина И.М., Батурина О.В.https://creativecommons.org/licenses/by/4.0https://klinitsist.abvpress.ru/Klin/article/view/109

The role of P2Y12 receptor blocker clopidogrel after the introduction into clinical practice of new, more powerful and stable operating drugs belonging to this class of antiplatelet agents is discussed. The advantages and disadvantages of each of the currently used antiplatelet drugs that block the receptor P2Y12 are reviewed. On the basis of the analysis concludes that, despite the emergence of new antiplatelet agents clopidogrel, appears to be widely used for a long time in the treatment of patients with acute coronary syndrome and / or after coronary stenting. This is primarily due to the presence of large evidence base, and confirmation of safety of long-term therapy clopidogrel.

статье обсуждается роль блокатора рецепторов P2Y12 клопидогрела после внедрения в клиническую практику новых, более мощных и стабильно действующих препаратов, относящихся к этому классу антиагрегантов. Рассматриваются преимущества и недостатки применения каждого из применяемых в настоящее время антиагрегантов, блокирующих рецепторы P2Y12. На основании выполненного анализа делается вывод о том, что несмотря на появление новых антиагрегантов клопидогрел, по-видимому, будет достаточно долго широко применяться в лечении пациентов с острым коронарным синдромом и/или перенесших коронарное стентирование. Это связано в первую очередь с наличием большой доказательной базы и подтверждением безопасности длительной терапии клопидогрелом.

acute coronary syndromemyocardial infarctionclopidogrelantithrombotic agentsострый коронарный синдроминфаркт миокардаклопидогрелантитромботические средства1. Fuster V., Badimon L., Badimon J.J., et al. Mechanisms of disease – the pathogenesis of coronary-artery disease and the acute coronary syndromes. N Engl J Med 1992;326:310–8.Fuster V., Badimon L., Badimon J.J., et al. Mechanisms of disease – the pathogenesis of coronary-artery disease and the acute coronary syndromes. N Engl J Med 1992;326:310–8.2. Lange R.A., Hillis L.D. Antiplatelet therapy for ischemic heart disease. N Engl J Med 2004;350:277–80.Lange R.A., Hillis L.D. Antiplatelet therapy for ischemic heart disease. N Engl J Med 2004;350:277–80.3. Dorsam R.T., Kunapuli S.P. Central role of the P2Y12 receptor in platelet activation. J Clin Invest 2004;113:340–5.Dorsam R.T., Kunapuli S.P. Central role of the P2Y12 receptor in platelet activation. J Clin Invest 2004;113:340–5.4. Gachet C. Regulation of platelet functions by P2 receptors. Annu Rev Pharmacol Toxicol 2006;46:277–300.Gachet C. Regulation of platelet functions by P2 receptors. Annu Rev Pharmacol Toxicol 2006;46:277–300.5. Patrono C., Baigent C., Hirsh J., Roth G., on behalf of American College of Chest Physicians. Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133 Suppl 6:199–233.Patrono C., Baigent C., Hirsh J., Roth G., on behalf of American College of Chest Physicians. Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133 Suppl 6:199–233.6. Kushner F.G., Hand M., Smith S.C. Jr., et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST elevation myocardial infarction (updating the 2004 guidelineKushner F.G., Hand M., Smith S.C. Jr., et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST elevation myocardial infarction (updating the 2004 guidelineand 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J AmColl Cardiol 2009;54:2205–41.7. Van de Werf F., Bax J., Betriu A., et al. ESC Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the TaskVan de Werf F., Bax J., Betriu A., et al. ESC Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the TaskForce on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008;29:2909–45.8. Authors/Task Force Members, Hamm C.W., Bassand J.P., Agewall S., et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent STsegmentAuthors/Task Force Members, Hamm C.W., Bassand J.P., Agewall S., et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent STsegmentelevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).Eur Heart J 2011 Aug 26 [Epub ahead of print].9. Anderson J.L., Adams C.D., Antman E.M., et al. 2011 Writing Group Members; ACCF/AHA Task ForceAnderson J.L., Adams C.D., Antman E.M., et al. 2011 Writing Group Members; ACCF/AHA Task ForceMembers. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-STElevation Myocardial Infarction: a reportof the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;123:e426–579.10. Ho P.M., Tsai T.T., Maddox T.M., et al. Delays in filling clopidogrel prescription after hospital discharge and adverse outcomes after drug-eluting stent implantation: implications for transitionsHo P.M., Tsai T.T., Maddox T.M., et al. Delays in filling clopidogrel prescription after hospital discharge and adverse outcomes after drug-eluting stent implantation: implications for transitionsof care. Circ Cardiovasc Qual Outcomes 2010;3:261–6.11. Snoep J.D., Hovens M.M., Eikenboom J.C., et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007;154:221–31.Snoep J.D., Hovens M.M., Eikenboom J.C., et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007;154:221–31.12. Brandt J.T., Close S.L., Iturria S.J., et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007;5:2429–36.Brandt J.T., Close S.L., Iturria S.J., et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007;5:2429–36.13. Hulot J.S., Bura A., Villard E., et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006;108:2244–7.Hulot J.S., Bura A., Villard E., et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006;108:2244–7.14. Bonello L., Camoin-Jau L., Arques S., et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008;51:1404–11.Bonello L., Camoin-Jau L., Arques S., et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008;51:1404–11.15. Bonello L., Camoin-Jau L., Armero S., et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009;103:5–10.Bonello L., Camoin-Jau L., Armero S., et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009;103:5–10.16. Cattaneo M. ADP receptors antagonists. In: Platelets. Michelson A.D., ed. San Diego, Calif: Elsevier Academic Press, 2006; p. 1127–44.Cattaneo M. ADP receptors antagonists. In: Platelets. Michelson A.D., ed. San Diego, Calif: Elsevier Academic Press, 2006; p. 1127–44.17. Cattaneo M. New P2Y(12) inhibitors. Circulation 2010;121:171–9.Cattaneo M. New P2Y(12) inhibitors. Circulation 2010;121:171–9.18. Farid N.A., Payne C.D., Small D.S., et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007;81:735–41.Farid N.A., Payne C.D., Small D.S., et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007;81:735–41.19. Wiviott S.D., Braunwald E., McCabe C.H., et al., for the TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–15.Wiviott S.D., Braunwald E., McCabe C.H., et al., for the TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–15.20. Serebruany V., Shalito I., Kopyleva O. Prasugrel development: claims and achievements. Thromb Haemost 2009;101:14–22.Serebruany V., Shalito I., Kopyleva O. Prasugrel development: claims and achievements. Thromb Haemost 2009;101:14–22.21. Storey R.F., Husted S., Harrington R.A., et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007;50:1852–6.Storey R.F., Husted S., Harrington R.A., et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007;50:1852–6.22. Husted S., Emanuelsson H., Heptinstall S., et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis:Husted S., Emanuelsson H., Heptinstall S., et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis:a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038–47.23. Cannon C.P., Husted S., Harrington R.A., et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, inCannon C.P., Husted S., Harrington R.A., et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, inpatients with non-ST-segment elevation acute coronary syndrome: primary results ofthe DISPERSE-2 trial. J Am Coll Cardiol 2007;50:1844–51 [Erratum, J Am Coll Cardiol 2007;50:2196].24. Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2009;361:1045–57.Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2009;361:1045–57.25. Hamm C.W., Bassand J.P., Agewall S., et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent STsegment elevation: The Task Force for theHamm C.W., Bassand J.P., Agewall S., et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent STsegment elevation: The Task Force for themanagement of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011 Aug 26 [Epub ahead of print].26. Crouch M.A., Colucci V.J., Howard P.A., Spinler S.A. P2Y12 Receptor Inhibitors: Integrating Ticagrelor into the Management of Acute Coronary Syndrome Ann Pharmacother SeptemberCrouch M.A., Colucci V.J., Howard P.A., Spinler S.A. P2Y12 Receptor Inhibitors: Integrating Ticagrelor into the Management of Acute Coronary Syndrome Ann Pharmacother September2011;45:1151–6.;45:1151–6.27. Spertus J.A., Kettelkamp R., Vance C., et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006;113:2803–9.Spertus J.A., Kettelkamp R., Vance C., et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006;113:2803–9.28. Eikelboom J.W., Hirsh J. Bleeding and management of bleeding. Eur Heart J 2006;8[Suppl]:G38–45.Eikelboom J.W., Hirsh J. Bleeding and management of bleeding. Eur Heart J 2006;8[Suppl]:G38–45.29. Mixed thoughts on how generic clopidogrel might impact patients, providers. HeartWire; August 11, 2006. Available from: http://www.theheart.org/article/729929.do.Mixed thoughts on how generic clopidogrel might impact patients, providers. HeartWire; August 11, 2006. Available from: http://www.theheart.org/article/729929.do.30. Haas J.S., Phillips K.A., Gerstenberger E.P., Seger A.C. Potential Savings from Substituting Generic Drugs for Brand-Name Drugs: Medical Expenditure Panel Survey, 1997–2000. Ann Intern Med 2005;Haas J.S., Phillips K.A., Gerstenberger E.P., Seger A.C. Potential Savings from Substituting Generic Drugs for Brand-Name Drugs: Medical Expenditure Panel Survey, 1997–2000. Ann Intern Med 2005;142:891–7.:891–7.31. Prescription Drug Trends—A Chartbook Update. Menlo Park, CA: Henry J. Kaiser Family Foundation, 2001.Prescription Drug Trends—A Chartbook Update. Menlo Park, CA: Henry J. Kaiser Family Foundation, 2001.32. Strom B.L. Generic drug substitution revisited. N Engl J Med 1987;316(23): 1456–62.Strom B.L. Generic drug substitution revisited. N Engl J Med 1987;316(23): 1456–62.33. Nightingale S.L. From the Food and Drug Administration. JAMA 1998;279:645.Nightingale S.L. From the Food and Drug Administration. JAMA 1998;279:645.34. 21 CFR (Code of Federal Regulations – Title 21: Food and Drugs). §320.1, 2000.21 CFR (Code of Federal Regulations – Title 21: Food and Drugs). §320.1, 2000.35. Shrank W., Cox E., Fischer M.A., et al. Patient perceptions of generic medications. Health Aff 2009;28:546–56.Shrank W., Cox E., Fischer M.A., et al. Patient perceptions of generic medications. Health Aff 2009;28:546–56.36. Banahan B.F., Bonnarens J.K., Bentley J.P. Generic substitution of NTI drugs. Formulary 1998;33:1082–96.Banahan B.F., Bonnarens J.K., Bentley J.P. Generic substitution of NTI drugs. Formulary 1998;33:1082–96.37. Gaither C., Kirking D., Ascione F., Welage L. Consumers’ views on generic medications. J Am Pharm Assoc 2001;41:729–36.Gaither C., Kirking D., Ascione F., Welage L. Consumers’ views on generic medications. J Am Pharm Assoc 2001;41:729–36.38. Saul S., Berenson A. Maker of Lipitor digs in to fight generic rival. New York Times Nov 3, 2007:A1.Saul S., Berenson A. Maker of Lipitor digs in to fight generic rival. New York Times Nov 3, 2007:A1.39. Kesselheim A.S., Misono A.S., Lee J.L., et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and metaanalysis. JAMA 2008;300:2514–26.Kesselheim A.S., Misono A.S., Lee J.L., et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and metaanalysis. JAMA 2008;300:2514–26.40. Ashraf T., Ahmed M., Talpur M.S., et al. Competency profile of locally manufactured clopidogrel Lowplat and foreign manufactured clopidogrel Plavix in patients of suspected ischemic heart disease.Ashraf T., Ahmed M., Talpur M.S., et al. Competency profile of locally manufactured clopidogrel Lowplat and foreign manufactured clopidogrel Plavix in patients of suspected ischemic heart disease.J Pak Med Assoc 2005;55:443–8.41. Rao T.R., Usha P.R., Naidu M.U., et al. Bioequivalence and tolerability study of two brands of clopidogrel tablets, using inhibition of platelet aggregation and pharmacodynamic measures. Curr Ther Res Clin Exp 2003;64:685–96.Rao T.R., Usha P.R., Naidu M.U., et al. Bioequivalence and tolerability study of two brands of clopidogrel tablets, using inhibition of platelet aggregation and pharmacodynamic measures. Curr Ther Res Clin Exp 2003;64:685–96.42. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, Bassand J.P., Hamm C.W., Ardissino D., et al. Guidelines for theTask Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, Bassand J.P., Hamm C.W., Ardissino D., et al. Guidelines for thediagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007:28:1598–660.